People · Operator
Named in public records as an officer, director or promoter · active 2009–2017 · Pharmaceuticals, Other Health Care, Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Eyenovia, Inc. | — | Pharmaceuticals | Series C | $66.0M | $312.6M | 2016 |
| Innocrin Pharmaceuticals Holdings, LLC | — | Pharmaceuticals | Series B | $42.1M | $204.0M | 2017 |
| Corinthian Ophthalmic, Inc. | — | Other Health Care | Seed | $12.9M | $40.6M | 2010 |
| Asepticys, LLC | — | Other | Seed | $4.2M | $49.3M | 2016 |
| XORI Corp | — | Biotechnology | Seed | $2.1M | $93.4M | 2009 |
FRED ESHELMAN at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside FRED ESHELMAN on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ernest Mario | 2 | 9 |
| Steve Gillis | 1 | 13 |
| Thong Le | 1 | 12 |
| Chad Waite | 1 | 11 |
| S Edward Torres | 1 | 8 |
| Anthony Sun | 1 | 8 |
| Carl Weissman | 1 | 8 |
| William Moore | 1 | 7 |
| Lindsay Rayle | 1 | 7 |
| Curt LaBelle | 1 | 7 |
| David Schubert | 1 | 6 |
| BARRY BUTLER | 1 | 6 |
| Richard Kent | 1 | 5 |
| Tsontcho Ianchulev | 1 | 5 |
| Steven Weinstein | 1 | 4 |
| James Rosen | 1 | 4 |
| Douglas Reed | 1 | 4 |
| JOHN MACK | 1 | 3 |
| Kenneth Lee | 1 | 2 |
| SEAN IANCHULEV | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.